Global Cord Blood (NYSE:CO) Earns Strong-Buy Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Global Cord Blood (NYSE:CO) in a report released on Thursday. The firm issued a strong-buy rating on the medical research company’s stock.

Global Cord Blood Stock Performance

Shares of CO stock remained flat at $1.25 during mid-day trading on Thursday. 36,719 shares of the stock were exchanged, compared to its average volume of 216,519. The firm’s 50 day simple moving average is $1.55 and its 200-day simple moving average is $1.39. The firm has a market cap of $151.94 million, a P/E ratio of 1.95 and a beta of 0.16. Global Cord Blood has a 1 year low of $2.03 and a 1 year high of $5.50.

About Global Cord Blood

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.